Transcript
Page 1: Evolving the Standard of Care— A Review of Afirma …...Expo Theater 2030 Boxed lunches will be served. Space is limited. First come, first served. JOIN US FOR A SPECIAL PRESENTATION:

OBJECTIVES:• Discuss Afirma Genomic Sequencing Classifier’s (GSC) impact in the

management of indeterminate thyroid nodules • Review initial Afirma GSC clinical experience data • Unveil the new Xpression Atlas

Program sponsored by Veracyte, Inc., provider of the Afirma Thyroid FNA Analysis

C841.1.1802

Giulia C. Kennedy, PhDChief Scientific and Medical OfficerVeracyte, Inc.

Richard T. Kloos, MDSenior Medical Director EndocrinologyVeracyte, Inc.

Christian Nasr, MD Staff Endocrinologist Medical Director, Thyroid CenterCleveland Clinic

SATURDAY, MARCH 171:00–2:00 PMExpo Theater 2030Boxed lunches will be served. Space is limited. First come, first served.

JOIN US FOR A SPECIAL PRESENTATION:Evolving the Standard of Care— A Review of Afirma GSC Experience Data andIntroducing the New Xpression Atlas

Top Related